🫁 Fibrosis pulmonar idiopática (#IPF)
🔬 China aprueba un nuevo fármaco innovador de clase 1
💊 #Nerandomilast comprimidos
📎 Más información: dengyuepharma.com
📧 info@dengyuemed.com
#FibrosisPulmonarIdiopática #EnfermedadPulmonar #Neumología #SaludPulmonar #DengYueMedicinasEnHongKong
FDA Grants Approval for JASCAYD® Tablets to Treat Progressive Pulmonary Fibrosis #United_States #Ridgefield #Pulmonary_Fibrosis #JASCAYD® #nerandomilast
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF Ingelheim, Germany, Friday, 24/10/2025 – 08 :00 CET Boehringer I...
#Lifestyle #& #Health #slider #Boehringer #Ingelheim […]
[Original post on executive-bulletin.com]
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF Ingelheim, Germany, Friday, 24/10/2025 – 08 :00 CET Boehringer I...
#Lifestyle #& #Health #slider #Boehringer #Ingelheim […]
[Original post on executive-bulletin.com]
Le Pr Crestani présente les #traitements innovants dans la fibrose pulmonaire - #taladegib, #nerandomilast et la #sarcoïdose chronique - #efzotimod
@hopitalbichat.bsky.social
#OrphaLung #RespiFil
🔴 #ERSCongress
Late breaking abstract - les résultats de la database lock final de l’essai #FIBRONEER-ILD du #nerandomilast dans la fibrose pulmonaire progressive présentés par Marlied S. Wijsenbeek #Netherlands #Rotterdam.
#OrphaLung
Remarkable: a treatment for progressive pulm. fibrosis #fibroticILD. #Nerandomilast a molecule with #antifibrotic and anti-inflammatory effect, slows down FVC deterioration. Additionally, a weak signal of benefit on secondary end points, seen beyond week 52 of therapy.
www.nejm.org/doi/full/10....
Should read this study carefully!
#Nerandomilast from @boehringerglobal.bsky.social an orally administered preferential inhibitor of phosphodiesterase 4B in #pulmonaryfibrosis. Results of a phase 3 study with background #antifibrotic therapy. #ATS2025
www.nejm.org/doi/full/10....
